Myomo (MYO) AI Stock Analysis

• Market Cap: $40.36M
• Dividend Yield: N/A
• Average Volume (3M): 807.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 64.99%
• EPS Growth: -25.54%
• Country: US
• Employees: 184
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 38,435,524
• 10 Day Avg. Volume: 913,590
• 30 Day Avg. Volume: 807,672
• PEG Ratio: 0.92
• Price to Book (P/B): 9.84
• Price to Sales (P/S): 7.47
• P/FCF Ratio: -52.30
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 1.35
• Enterprise Value/Ebitda: -3.70
• 1Y Price Target: $6.33
• Price Target Upside: 465.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.37
• Revenue Forecast (FY): $39.99M

• Rating: 51 Neutral
• Price Target: $1.00 ▼(-10.71% Downside)

The overall stock score reflects a balance between strong revenue growth and strategic initiatives against the backdrop of profitability and cash flow challenges. The recent loan provides financial support, but the company must address operational inefficiencies to improve its financial health.

Positive Factors

Revenue Growth

Significant growth in the O&P channel indicates strong demand and successful market penetration, supporting long-term revenue expansion.

International Market Success

Strong international performance, especially in Germany, highlights Myomo's ability to expand globally, diversifying revenue streams and reducing reliance on domestic markets.

Financial Flexibility

The new loan enhances financial flexibility, allowing Myomo to invest in growth initiatives and manage operational needs, supporting long-term strategic goals.

Negative Factors

Decreased Gross Margin

A decline in gross margin due to higher costs could pressure profitability, requiring efficiency improvements to maintain long-term financial health.

Increased Operating Loss

Rising operating losses highlight challenges in cost management, which could hinder profitability and require strategic adjustments to improve financial performance.

High Cash Burn

High cash burn indicates potential liquidity issues, necessitating improved cash flow management to ensure sustainable operations and future growth.

Myomo Business Overview & Revenue Model

Company Description

Myomo, Inc. (MYO) is a medical technology company that specializes in the development of innovative wearable solutions for individuals with neuromuscular disorders. The company focuses primarily on creating advanced powered orthotics, specifically myoelectric braces, designed to restore mobility and enhance the quality of life for patients suffering from conditions such as stroke, spinal cord injury, and other neurological impairments. Myomo's flagship product, the MyoPro, is a lightweight, non-invasive device that detects muscle signals and translates them into movement, allowing users to regain functional use of their arms and hands.

How the Company Makes Money

Myomo generates revenue primarily through the sale of its MyoPro orthotic devices, which are sold directly to healthcare providers and through various distribution channels. The company also benefits from reimbursement programs that allow patients to have their MyoPro devices covered by insurance, which significantly enhances market access and sales potential. Additionally, Myomo collaborates with healthcare institutions and rehabilitation centers to provide customized solutions and services, further expanding its reach and revenue potential. Strategic partnerships with medical professionals, rehabilitation facilities, and insurance providers play a crucial role in driving sales and increasing the adoption of its products.

Myomo Financial Statement Overview

Summary

Myomo is experiencing revenue growth, but profitability and cash flow challenges persist. The company has increased its leverage, which could pose risks if not managed carefully. Improving operational efficiency and cash flow generation are critical for enhancing financial stability and long-term success.

Income Statement

The company has shown consistent revenue growth, with a TTM revenue growth rate of 2.17%. However, profitability remains a challenge, as indicated by negative net profit and EBIT margins. The gross profit margin is relatively strong at 69.24%, but the company needs to address its operational inefficiencies to improve overall profitability.

Balance Sheet

The debt-to-equity ratio has increased to 0.71 in the TTM period, indicating a rise in leverage. Return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly provided, but the balance sheet shows a moderate level of equity relative to total assets. The company needs to manage its debt levels and improve its equity position.

Cash Flow

Cash flow remains a significant concern, with negative operating and free cash flows. The free cash flow to net income ratio is above 1, indicating that cash flow is less negative than net income, but the overall cash flow position is weak. The company must focus on improving cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.64M	32.55M	19.24M	15.56M	13.86M	7.58M
Gross Profit	27.72M	23.19M	13.18M	10.25M	10.31M	4.98M
EBITDA	-10.10M	-5.04M	-7.71M	-10.13M	-9.93M	-10.98M
Net Income	-12.02M	-6.18M	-8.15M	-10.72M	-10.37M	-11.56M
Balance Sheet
Total Assets	34.08M	42.24M	14.58M	10.16M	20.10M	14.71M
Cash, Cash Equivalents and Short-Term Investments	12.55M	24.87M	8.87M	5.35M	15.52M	12.24M
Total Debt	12.30M	8.11M	601.30K	553.91K	735.00K	173.44K
Total Liabilities	19.45M	17.53M	5.59M	3.80M	4.69M	3.14M
Stockholders Equity	14.63M	24.71M	8.99M	6.36M	15.41M	11.57M
Cash Flow
Free Cash Flow	-13.85M	-4.65M	-6.32M	-10.35M	-9.87M	-9.08M
Operating Cash Flow	-10.01M	-3.29M	-6.17M	-10.23M	-9.55M	-9.03M
Investing Cash Flow	-3.82M	259.98K	-2.03M	-310.79K	-326.46K	-45.75K
Financing Cash Flow	19.68M	20.93M	9.71M	376.86K	13.17M	16.78M

Myomo Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Neutral. The current price of 1.12 is above the 20-day moving average (MA) of 0.90, above the 50-day MA of 0.96, and below the 200-day MA of 2.40, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.46 is Neutral, neither overbought nor oversold. The STOCH value of 76.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYO.

Myomo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ECOR	59 Neutral	$38.54M	―	-337.84%	―	27.90%	1.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYO	51 Neutral	$40.36M	―	-100.51%	―	64.99%	-25.54%
ADGM	46 Neutral	$17.79M	―	-210.36%	―	-70.54%	70.03%
RBOT	39 Underperform	$30.45M	-0.46	-148.93%	―	―	15.03%
IINN	35 Underperform	$31.80M	-2.41	―	―	―	―

Myomo Corporate Events

Myomo Secures $17.5 Million Loan for Growth

On November 4, 2025, Myomo, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P., securing up to $17.5 million in term loans. This financial arrangement aims to support Myomo’s operational needs, including repaying existing borrowings and general corporate purposes. The company reported a strong third quarter in 2025, with revenues reaching $10.1 million, a 10% increase from the previous year, driven by record levels in both U.S. and international O&P revenues. Despite a decrease in gross margin due to higher costs, Myomo is focusing on cost reduction projects and strategic marketing initiatives like MyoConnect to enhance its patient pipeline and reduce costs.